Responder.bio

Imputation · powered by Responder Atlas

Structure to indication signal, instantly.

Paste a SMILES string. Imputation queries Responder Atlas — our platform built on public pharmacogenomic data — and returns a ranked signal across 17 cancer tissue types with a confidence tier from chemical similarity to the training set. No account needed.

Input

Paste a molecule's SMILES notation. Full SMILES validation is deferred — for now only a non-empty string is required.

Example

Sample result — gefitinib

This is an illustrative sample so you can see the format. Submit a SMILES above to get your own prediction. The values below come from our committed gefitinib report — they are not tied to anything you've typed.

Confidence & provenance

elevated

Basis: SMILES imputedModel: v0.3

Max Tanimoto
1.00
Nearest training drug
gefitinib
Neighbours ≥ 0.5
5

This compound is not in the training set — signal is imputed from chemical structure.

chemistry-similarity tier (max ECFP4 Tanimoto to v0.3 training set): elevated >=0.5 (committed node-rank rho ~0.62, 62.5% reach rho>0.5); moderate 0.4-0.5 (rho ~0.50, 50%); exploratory <0.4 (rho ~0.30, ~18%). Estimated, not guaranteed (committed outlier: doxorubicin tanimoto 1.0 yet rho 0.46).

Ranked indications

6 indications · server-ranked

  1. 01Esophaguselevated
    Predicted viability change+44.2%

    reduces viability — predicted cell killing

    Selectivity vs. this drug's average+62%

    more responsive than this drug's own average

  2. 02Upper Aerodigestiveelevated
    Predicted viability change+32.6%

    reduces viability — predicted cell killing

    Selectivity vs. this drug's average+34%

    more responsive than this drug's own average

  3. 03Urinary Tractelevated
    Predicted viability change+30.5%

    reduces viability — predicted cell killing

    Selectivity vs. this drug's average+30%

    more responsive than this drug's own average

  4. 04Pancreaselevated
    Predicted viability change+18.7%

    reduces viability — predicted cell killing

    Selectivity vs. this drug's average+11%

    more responsive than this drug's own average

  5. 05Uteruselevated
    Predicted viability change+17.5%

    reduces viability — predicted cell killing

    Selectivity vs. this drug's average+10%

    more responsive than this drug's own average

  6. 06Ovaryelevated
    Predicted viability change+14.8%

    reduces viability — predicted cell killing

    Selectivity vs. this drug's average+6%

    more responsive than this drug's own average

Two different things. Predicted viability change is the absolute effect — whether the drug is predicted to reduce viability (kill; bar right of zero) or increase it (proliferate; bar left). Selectivity is how that indication compares to this drug's own average across all indications (bar right = more responsive). Both bars diverge around a zero line.

Preview shows the top 6 of 17 indications. A real submission returns the full ranked list.